北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 胃肠肿瘤中心  > 期刊论文
学科主题: 临床医学
题名:
Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor
作者: Li, J.1; Gong, J. F.1; Wu, A. W.2; Shen, L.1
关键词: Adjuvant therapy ; Gastrointestinal stromal tumor ; Imatinib ; Recurrence-free survival ; c-KIT
刊名: EJSO
发表日期: 2011-04-01
DOI: 10.1016/j.ejso.2011.01.005
卷: 37, 期:4, 页:319-324
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Surgery
研究领域[WOS]: Oncology ; Surgery
关键词[WOS]: TERM-FOLLOW-UP ; RECURRENCE RATES ; EXPERIENCE ; MESYLATE ; PATTERNS ; GIST
英文摘要:

Aims; This study aims to determine whether adjuvant treatment with imatinib improves recurrence-free survival (RFS) in Chinese patients undergoing complete resection of localized primary gastrointestinal stromal tumor (GIST) compared with those not receiving adjuvant therapy. We also sought a correlation between c-KIT mutations and RFS.

Methods: Patients who had undergone complete tumor resection with intermediate or high risk of recurrence were enrolled in a single-center, non-randomized, prospective study. Patients either received adjuvant imatinib therapy (400 mg once-daily) for 3 years or did not. Mutation analyses of c-KIT were performed on available archival tumor samples.

Results: 105 patients were enrolled: 56 in the treatment group and 49 in the control group. Median follow-up was 45(43.1-46.9) months. RFS at 1, 2 and 3 years were higher in the treatment group than in the control group (100% vs. 90% at I year; 96% vs. 57% at 2 years; 89% versus 48% at 3 years, P < 0.001, HR = 0.188). Subgroup analyses showed that adjuvant therapy significantly decreased the risk of recurrence in patients whether at high risk or at intermediate risk compared with control patients (3-year RFS: 95% vs. 72%, in intermediate risk; 85% versus 31% in high risk; P < 0.001). In addition, imatinib adjuvant treatment decreased the risk of death (P = 0.039, HR = 0.254).

Conclusions: Adjuvant imatinib can improve 1-, 2- and 3-year RFS rates in patients at intermediate or high risk of recurrence after complete tumor resection. Clinical Trials Registration Number: ChiCTR-TCC-00000582 (C) 2011 Elsevier Ltd, All rights reserved.

语种: 英语
所属项目编号: 08-17
项目资助者: Beijing Cancer Hospital Foundation ; Novartis Oncology
WOS记录号: WOS:000289337400006
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53893
Appears in Collections:北京大学临床肿瘤学院_胃肠肿瘤中心_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ, Sch Oncol,Beijing Canc Hosp & Inst,Dept GI Oncol, Beijing 100142, Peoples R China
2.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Gastrointestinal Surg, Beijing 100142, Peoples R China

Recommended Citation:
Li, J.,Gong, J. F.,Wu, A. W.,et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor[J]. EJSO,2011,37(4):319-324.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li, J.]'s Articles
[Gong, J. F.]'s Articles
[Wu, A. W.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li, J.]‘s Articles
[Gong, J. F.]‘s Articles
[Wu, A. W.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace